fbpx

BONESUPPORT ANNOUNCES CE-MARK OF CERAMENTT’V, THE FIRST INJECTABLE VANCOMYCIN ELUTING BONE SUBSTITUTE IN THE MANAGEMENT OF OSTEOMYELITIS

“Antibiotic resistant infections are among the most challenging clinical conditions to manage, said Pablo S. Corona, M.D., PhD, from the Reconstructive and Septic Surgery Division, Department of Orthopaedic Surgery, Hospital de Traumatologia y Rehabilitacion Vall d’Hebron, Barcelona, Spain. “Local, high dose antibiotic delivery is particularly effective in managing and preventing infections, as seen with CERAMENTT’G.  Now with the availability of CERAMENTT’V, surgeons have two powerful weapons that address the most common bacteria in the fight against osteomyelitis.”

CERAMENTT’V is an injectable, resorbable bone graft substitute which remodels into healthy native bone within 6 to 12 months, and is designed to fill bone gaps and voids and can augment hardware and bone fractures during surgical procedures.  The efficient elution profile and the focused local delivery of vancomycin obtained with CERAMENTT’V is intended to prevent colonization of sensitive microorganisms, thereby protecting the bone healing, particularly in challenging cases of deep bone infection.

“Expanding our portfolio of drug-delivery therapeutics is an important part of our growth strategy and we are proud to be executing on that with the launch of CERAMENTT’V,” said Lloyd Diamond, CEO of BONESUPPORT.  “As a pioneer of antibiotic eluting bone substitute technology, the launch of CERAMENTT’V marks the first ever injectable bone substitute with two drugs, vancomycin and Iohexol, to receive approval.  This is an important milestone because it paves the way for future drug delivery combinations using our propriety technology and the CERAMENTT platform.”

Osteomyelitis, or Bone Infection is a $1.7 billion market where prolonged, long-term antibiotic therapy, multiple surgical interventions and the threat of amputation are the current standard of care. Rising prosthetic infections, diabetic ulcers, war injuries, sports injuries, and an increasing resistance to antibiotics contribute to this growing condition.

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedics, and trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENTT is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENTT’G and CERAMENTT’V are the first CE-marked injectable antibiotic eluting ceramic bone graft substitutes indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections). CERAMENT’s unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENTT’G and CERAMENTT’V are not available in the United States.

CERAMENTT is a fully developed product platform that is commercially available in the U.S., Europe, SE Asia and the Middle East. CERAMENTT is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and more than 10,000 patients have been treated with CERAMENT.  The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.

Press Inquiries:

Offer Nonhoff

Chief Financial Officer

Offer.Nonhoff@bonesupport.com

Phone +46 46 286 53 60

PR 0410-01 en

News

DNA analysis of 442 Viking skeletons rewrites the story of Viking culture
16. September 2020
Hope that a brain injection could cure type 2 diabetes
7. September 2020
Maude has become the stereotypical migraine patient – but it’s not quite the true picture
31. July 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge